EXTENDED REPORT

Parental history of lupus and rheumatoid arthritis and risk in offspring in a nationwide cohort study: does sex matter?

Emily C Somers,1,2,3 Sussie Antonsen,3 Lars Pedersen,3 Henrik Toft Sørensen3

ABSTRACT

Objectives To examine the familial risk of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), including juvenile rheumatoid/pediatric arthritis (JRA), in a population-based setting; and to determine whether patterns of transmission differ according to the sex of the parent or offspring, in order to provide insight into the potential impact of X-chromosomal factors on sex disparities in these autoimmune diseases.

Methods A population-based cohort of parent–offspring triads from Denmark (1977–2010) was established. SLE and RA incidence rates among offspring were calculated, and Cox regression was performed to assess the sex-specific risk of disease in offspring according to maternal or paternal disease history.

Results Among 3,513,817 parent–offspring triads, there were 1258 SLE cases among offspring (1095 female, 163 male) and 9118 cases of RA/JRA (6086 female, 3032 male). Among female offspring, SLE risk was nearly the same according to maternal (HR 14.1) or paternal (HR 14.5) history (p = NS); likewise among male offspring, risk according to maternal (HR 5.5) and paternal (no cases) history were similar (p = NS). For RA, all risk estimates were similar, regardless of the sex of the offspring or parent (HR 2.6–2.8; p = NS).

Conclusions The authors quantified the familial risk of SLE and RA in a nationwide cohort study. For both diseases, transmission was comparable among both female and male offspring of maternal and paternal cases. These data provide evidence at the population level that X-chromosomal factors do not play a major role in sex disparities associated with the risk of SLE and RA.

Like the majority of autoimmune diseases, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) disproportionately affect women, with female to male ratios of up to 9:1. Although sex steroid hormones probably contribute to the increased incidence observed among women, this explanation is simplistic. Genomic differences between men and women may play a role in autoimmune and other immunological diseases, and X-chromosomal factors, including X-linked susceptibility genes or incomplete X inactivation, have been hypothesised to contribute to the female preponderance of these diseases. It is estimated that the X chromosome contains close to 6% of genomic DNA in humans, or approximately 1100 known genes. Recent studies have suggested potential alleles on the X chromosome that may be relevant to RA and SLE, and investigation of candidate genes on the X chromosome that may be associated with autoimmune disorders is ongoing.

Familial aggregation has been identified for many autoimmune diseases, including SLE and RA. For instance, based on data from case–control studies, it has been estimated that offspring of a parent with SLE have more than three times the risk of developing SLE compared with controls with no family history (OR 3.3, 95% CI 1.2 to 8.6); a similar degree of risk for developing RA among offspring with an affected parent has been reported (OR 3.5, 95% CI 1.1 to 10.8). However, familial data for SLE and RA have often been derived from multiplex families recruited for genetics studies, which by definition include families with more than one case of disease. Also, it is unclear whether risk differs for maternal versus paternal transmission, or according to the sex of the offspring. Men have single X chromosomes, with all cells having maternally derived alleles on the X chromosome. While women inherit both maternal and paternal X chromosomes, only a single ‘active’ X chromosome is normally expressed in each cell (transcription of the inactive X is silenced). Epigenetic mechanisms (gene modifications other than alterations in the DNA sequence), such as DNA methylation, are responsible for inactivation of the second X chromosome. The process of X chromosome inactivation is purportedly random, and therefore is expected to yield approximately equivalent proportions of cells in women who express maternal or paternal X alleles. If there are important risk allele(s) on the X chromosome, male offspring of mothers with SLE or RA would be expected to have a higher risk of disease than male offspring of affected fathers, because sons do not inherit a paternal X chromosome. Female offspring, however, would be expected to experience an equivalent magnitude of familial association regardless of whether the parental proband was maternal or paternal. If such patterns were refuted utilising population-based data, it would suggest that X-linked chromosomes do not play a substantial role in disease risk. Identification of differential risks would provide aetiological clues.

Laboratory research related to the intersection of sex, genetics and epigenetics in autoimmune diseases is ongoing, with a lack of complementary epidemiological data. We conducted this population-based study, utilising Danish registry data, to further understanding of the familial risk of disease and sex disparities in the risk of two major systemic autoimmune diseases—RA and SLE.
METHODS

Study population
This population-based cohort study used linked Danish health registries for the period 1 January 1977 to 1 January 2010. The Danish Civil Registration System was utilised to produce individual-level data linkages, and also to establish parent–offspring linkages, which are available from 1950 onward. The Danish National Registry of Patients provided diagnostic data, based on the International Classification of Diseases (ICD) coding structure (ICD-8 until 1993; ICD-10 from 1994 onward). This database records hospitalisations since 1977 and outpatient visits since 1995. Further details regarding Danish registry data are described elsewhere.17–19 This research was approved by the Danish ethical review boards and the Danish Data Protection Agency.

Cases of SLE and RA, including juvenile rheumatoid/idiopathic arthritis (JRA), were identified based on relevant ICD-8 and ICD-10 diagnostic codes (see supplementary appendix, available online only). The date of the first ICD code for a given disease in the patient record was considered the diagnosis date.

Statistical methods
The analysis included all offspring–parent triads followed up during the study period. SLE and RA history, including diagnosis dates, were determined for all offspring and parents. Analyses were carried out separately for female and male offspring, in order to investigate sex-specific effects. Crude incidence rates of disease among the offspring, according to maternal and paternal history of disease, were calculated by dividing the number of cases by person-time at risk, expressed per 100 000 person-years. In order to take into account person-time at risk, Cox proportional hazards regression was performed, using a left-truncated approach and with offspring age as the timescale.20 21 Both maternal and paternal disease histories were included as covariates in the primary models. Sensitivity analyses were conducted to account for calendar period, by adjusting for the year of birth, in 5-year groups, in the modelling. Further sensitivity analyses were conducted in which families with more than one affected offspring were excluded, so that these families were not over-weighted in the analyses. The Wald χ² statistic was used to compare hazard ratios (HR) between maternal and paternal history. Data management and analysis was performed using SAS v9.2 software.

RESULTS

The study population included 3 513 817 eligible parent–offspring triads. Of these, 1015 female offspring and 1344 male offspring had less than 1 day at risk (due to neonatal death) and were thus excluded from analyses incorporating person-time. There was a total of 1258 cases of SLE among offspring (1095 female, 163 male) and 9118 cases of RA/JRA among offspring (6036 female, 3052 male). Table 1 presents incidence rates and HR with 95% CI corresponding to maternal and paternal history of disease, stratified by the sex of the offspring.

A parental history of SLE was strongly associated with the risk of SLE in offspring (HR >14.0 among female offspring for either maternal or paternal history; HR 5.5 among male offspring for maternal history; HR zero for paternal history due to absence of cases). A parental history of RA was also associated with increased risk of RA among offspring at statistically significant levels, compared with offspring without a parental history of RA. However, magnitudes of association were weaker than those observed for SLE (HR ranging from 2.4 to 2.9 in female and male offspring). When JRA cases were included in the total for RA, HR were similar to those for RA cases alone (HR ranging from 2.4 to 2.7).

As presented in table 1, when HR for maternal versus paternal history of disease were compared according to the sex of

<table>
<thead>
<tr>
<th>Parental history of disease</th>
<th>Female offspring</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th>Male offspring</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No of cases</td>
<td>Person-time at risk</td>
<td>Crude rate/100 000 person-years</td>
<td>HR (95% CI)*</td>
<td>p Value†</td>
<td>No of cases</td>
<td>Person-time at risk</td>
<td>Crude rate/100 000 person-years</td>
<td>HR (95% CI)*</td>
<td>p Value†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maternal SLE</td>
<td>No</td>
<td>1078</td>
<td>40 656 405</td>
<td>2.7</td>
<td>Referent</td>
<td>0.9588</td>
<td>162</td>
<td>44 269 324</td>
<td>0.4</td>
<td>Referent</td>
<td>0.9753</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>17</td>
<td>44 889</td>
<td>36.3</td>
<td>14.1 (8.7 to 22.8)</td>
<td>1</td>
<td>48 468</td>
<td>2.0</td>
<td>5.5 (0.8 to 39.3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paternal SLE</td>
<td>No</td>
<td>1090</td>
<td>40 690 357</td>
<td>2.7</td>
<td>Referent</td>
<td>163</td>
<td>44 306 784</td>
<td>0.4</td>
<td>Referent</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>5</td>
<td>10 937</td>
<td>45.3</td>
<td>14.5 (6.0 to 34.9)</td>
<td>0</td>
<td>11 008</td>
<td>–</td>
<td>0 (0)‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maternal RA</td>
<td>No</td>
<td>4301</td>
<td>40 202 250</td>
<td>10.7</td>
<td>Referent</td>
<td>1882</td>
<td>43 767 476</td>
<td>4.3</td>
<td>Referent</td>
<td>0.4651</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>203</td>
<td>483 783</td>
<td>42.0</td>
<td>2.7 (2.4 to 3.1)</td>
<td>86</td>
<td>541 077</td>
<td>15.9</td>
<td>2.6 (2.1 to 3.2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paternal RA</td>
<td>No</td>
<td>4394</td>
<td>40 439 961</td>
<td>10.9</td>
<td>Referent</td>
<td>1916</td>
<td>44 026 469</td>
<td>4.4</td>
<td>Referent</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>110</td>
<td>246 073</td>
<td>44.7</td>
<td>2.8 (2.4 to 3.4)</td>
<td>52</td>
<td>282 083</td>
<td>18.4</td>
<td>2.9 (2.2 to 3.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maternal RA/JRA</td>
<td>No</td>
<td>5850</td>
<td>40 190 344</td>
<td>14.6</td>
<td>Referent</td>
<td>2931</td>
<td>43 757 816</td>
<td>6.7</td>
<td>Referent</td>
<td>0.5844</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>236</td>
<td>485 075</td>
<td>48.7</td>
<td>2.7 (2.4 to 3.1)</td>
<td>101</td>
<td>542 649</td>
<td>18.6</td>
<td>2.4 (2.0 to 2.9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paternal RA/JRA</td>
<td>No</td>
<td>5964</td>
<td>40 427 902</td>
<td>14.8</td>
<td>Referent</td>
<td>2974</td>
<td>44 017 063</td>
<td>6.8</td>
<td>Referent</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>122</td>
<td>247 517</td>
<td>49.3</td>
<td>2.7 (2.2 to 3.2)</td>
<td>58</td>
<td>283 400</td>
<td>20.5</td>
<td>2.6 (2.0 to 3.4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Adjusted for maternal/paternal history.
†p Value comparing maternal versus paternal history risk estimates.
‡Upper bound not calculated due to no cases among male offspring.
JRA, juvenile rheumatoid/idiopathic arthritis; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis.
The offspring, magnitudes of risk were similar regarding either parent, both for SLE and RA (all p values NS). Results did not differ appreciably after adjustment for calendar period (in 5-year groups; table 2).

There were 12 families with SLE in more than one offspring (all with SLE in two offspring). For RA, 132 families had the disease in more than one offspring (128 families with two offspring and four families with more than two offspring affected). Results from sensitivity analyses excluding families with more than one affected offspring yielded numbers similar to those from the main models (table 2).

**DISCUSSION**

While familial aggregation of SLE and RA has long been recognised, our study is unique in its population-based design and focus on intergenerational patterns between parents and their offspring, rather than within more broadly defined first or second degree kinships. In addition, we accounted for the age of the offspring and person-time at risk. We also analysed incident cases, instead of simply reporting proportions of prevalent cases among offspring of affected relatives.

Our data extend former research. We thus showed in the Danish population, that a parental history of SLE is associated with up to a 14-fold increased risk of SLE among offspring, compared with a negative parental history of SLE. The magnitude of this risk is substantially higher than previous reports, suggesting that earlier studies may have underestimated familial risk. In contrast, our estimates for RA (HR ranging from 2.6 to 2.9) correspond more closely to previous data. SLE and RA are both complex diseases with multifactorial aetiologies involving the interplay of genetic and environmental factors. Our data imply that the genetic basis of SLE may be stronger than that for RA. Other lines of epidemiological evidence, such as temporal trends, also lend credence to this theory. For instance, while data indicate that the incidence of SLE has been relatively stable over calendar time, the incidence of RA in recent decades has been estimated to be decreasing, indicating a modulation of RA risk by environmental factors.

When we examined whether a parental history of disease had a differential impact according to the sex of the parent or offspring, we confirmed that female offspring are at greater risk of disease than male offspring. This is consistent with well-recognised higher incidence rates among female offspring. As hypothesised, for both SLE and RA, similar magnitudes of risk were observed among female offspring in association with a maternal or paternal history of disease. However, our data did not support the hypothesis that among male offspring a maternal history of disease would be associated with a greater magnitude of risk compared with a paternal history of disease. Rather, similar levels of risk were also seen among male offspring with maternal versus paternal disease history. Our results remained consistent in sensitivity analyses accounting for calendar time, and after the exclusion of families with more than one affected offspring case.

An overarching question in autoimmune disease research is which factors drive the strong female preponderance of disease. The idea that sex-chromosomal factors are involved is intriguing, and epidemiological research is needed in concert with basic science research in this area. Candidate X-chromosomal genes that may be associated with autoimmune diseases are recognised higher incidence rates among female offspring. As hypothesised, for both SLE and RA, similar magnitudes of risk were observed among female offspring in association with a maternal or paternal history of disease. However, our data did not support the hypothesis that among male offspring a maternal history of disease would be associated with a greater magnitude of risk compared with a paternal history of disease. Rather, similar levels of risk were also seen among male offspring with maternal versus paternal disease history. Our results remained consistent in sensitivity analyses accounting for calendar time, and after the exclusion of families with more than one affected offspring case.

**Table 2** Sensitivity analyses adjusted for birth year and excluding families with more than one offspring with disease

<table>
<thead>
<tr>
<th>Parental history of disease</th>
<th>Female offspring</th>
<th></th>
<th>Male offspring</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adjusted for birth year</td>
<td>Excluding families with more than one affected offspring</td>
<td>Adjusted for birth year</td>
<td>Excluding families with more than one affected offspring</td>
</tr>
<tr>
<td></td>
<td>HR (95% CI)*</td>
<td>p Value†</td>
<td>HR (95% CI)*</td>
<td>p Value†</td>
</tr>
<tr>
<td>Maternal SLE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>14.1 (8.7 to 22.80)</td>
<td>0.9059</td>
<td>Referent</td>
<td>0.7710</td>
</tr>
<tr>
<td>Yes</td>
<td>Referent</td>
<td>12.7 (7.6 to 21.2)</td>
<td>5.6 (8.9 to 39.6)</td>
<td>Referent</td>
</tr>
<tr>
<td>Paternal SLE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>15.0 (6.2 to 36.1)</td>
<td>0.7136</td>
<td>Referent</td>
<td>0.5984</td>
</tr>
<tr>
<td>Yes</td>
<td>Referent</td>
<td>2.6 (2.2 to 3.0)</td>
<td>2.6 (2.1 to 3.2)</td>
<td>Referent</td>
</tr>
<tr>
<td>Maternal RA/JRA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>2.9 (2.4 to 3.5)</td>
<td>0.9909</td>
<td>Referent</td>
<td>0.7453</td>
</tr>
<tr>
<td>Yes</td>
<td>Referent</td>
<td>2.5 (2.2 to 2.9)</td>
<td>2.6 (2.1 to 3.2)</td>
<td>Referent</td>
</tr>
<tr>
<td>Paternal RA/JRA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>2.9 (2.4 to 3.5)</td>
<td>Referent</td>
<td>Referent</td>
<td>2.6 (2.2 to 3.7)</td>
</tr>
<tr>
<td>Yes</td>
<td>Referent</td>
<td>Referent</td>
<td>Referent</td>
<td>Referent</td>
</tr>
</tbody>
</table>

*Also adjusted for maternal/paternal history.
†p Value comparing maternal versus paternal history risk estimates.
‡Upper bound not calculated due to no cases among male offspring.
JRA, juvenile rheumatoid/idiopathic arthritis; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis.
separate genetic associations. Another line of investigation is the identification of X-chromosomal genes with functional relevance to autoimmune disease. For instance, abnormalities in apoptosis have been observed in autoimmune diseases such as SLE, and at least 17 X chromosome genes, including CD40LG, have apoptosis listed as a gene ontology term. However, our epidemiological findings of similar magnitudes of risk, regardless of the sex of the affected parent, indicate that for both SLE and RA, genetic factors associated with the sex chromosomes do not play a major role in disease risk at the population level. Coupled with the observation that individual single nucleotide polymorphisms recognised as being associated with SLE and RA correspond to small magnitudes of risk (OR individually <2), our findings may imply that epigenetic rather than genetic factors are relevant to the sex disparities observed in the risk of these autoimmune diseases.

Incomplete inactivation of the second X chromosome in women may be one epigenetic mechanism involved in autoimmune disease, by allowing the overexpression of X-chromosomal genes in women. Lu et al. provided evidence that demethylation of regulatory sequences on the inactive X chromosome and associated overexpression may be a factor in autoimmune disease. They found that CD40LG (a B-cell co-stimulatory molecule, encoded on the X chromosome) is unmethylated in men, while women have both a methylated and an unmethylated copy. Moreover, they demonstrated in a series of experiments on T cells isolated from lupus patients that CD40LG is overexpressed on CD4 T cells in women, but not men, corresponding to demethylation of CD40LG in women. Research is ongoing to determine if similar findings apply to other genes on the inactive X chromosome. A non-genomic concept that should be considered in the context of the parental origin of effects is the transmission of non-inherited maternal antigens (NIMA), which can occur transplacentally or by breastfeeding. Exposure to NIMA may influence immune modelling, and NIMA have been associated with both an increased and decreased risk of RA, whereas data do not support a role for NIMA in association with the risk of SLE.

Our results contrast with those from a US-based registry study of SLE multiplex families, in which 22% of 68 SLE parents with SLE offspring were men. This led the authors to infer that men were overrepresented as parents of offspring with SLE. However, because that study was composed of families with at least two SLE cases rather than being population based, it may have been subject to selection biases, such as the inclusion of cases with greater genetic risk or disease severity, or a greater tendency for men with affected offspring to participate due to the rarity of SLE in men.

A phenomenon termed the ‘Carter effect’, first described for pyloric stenosis, predicts a greater magnitude of disease transmission in the sex with the lower baseline predisposition for disease (men in the cases of SLE and RA), based on the theory that a greater genetic load would be necessary for disease penetrance in the less affected sex. Support for the Carter effect was reported for multiple sclerosis, another autoimmune disease with a female preponderance, but was refuted in another study. While a higher genetic load has recently been reported for multiple sclerosis, another autoimmune disease with a female preponderance, but was refuted in another study. While there may have been some misclassification of case status, such misclassification would be expected to be non-differential, and would therefore be expected to attenuate the reported risk estimates. Due to the small number of male SLE patients (in particular among male offspring), there may have been insufficient power to detect potential sex-dependent effects for this diagnosis. Another concern is that family linkages were based on administrative data, not permitting us to confirm biological parental status. Also, we were unable to assess the contribution of environmental factors, which may also cluster in families, to disease expression.

A future direction will be to explore the possibility of genetic anticipation in the SLE and RA populations, which would be exhibited by a younger age of onset and increased disease severity among second generation cases. As a simple comparison of age of onset distributions from each generation is inappropriate due to statistical considerations such as right truncation, various methods have been developed for the study of genetic anticipation, including newer methods that incorporate data from unaffected family members. Another direction will be to investigate familial autoimmunity in broader terms, rather than focusing on the patterns of single diseases within families. Various combinations of autoimmune diseases have been shown to cluster within families and individuals, and shared heritable pathogenic factors, such as dysregulation of the interferon-α system in several autoimmune conditions, have been suggested. While autoimmune diseases may have genetic and environmental risk factors in common, the interplay of such factors may influence the particular autoimmune phenotypes that are expressed.

In conclusion, our study shows a strong familial risk for SLE and a more moderate familial risk for RA. For both diseases, we found equivalent disease transmission among both female and male offspring of maternal compared with paternal cases. These results do not support the concept of the Carter effect in SLE or RA, and provide indirect evidence on a population level that X-chromosomal factors do not play a major role in sex disparities observed for the risk of SLE and RA.

Acknowledgements The authors would like to thank Bruce Richardson for critical review of the manuscript.

Competing interests None.

Funding This study was supported by an Arthritis Foundation New investigator award and an Elizabeth C Crosby research award (both to ECS) and by the Aarhus University Clinical Research Foundation.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


4 of 5


Parental history of lupus and rheumatoid arthritis and risk in offspring in a nationwide cohort study: does sex matter?

Emily C Somers, Sussie Antonsen, Lars Pedersen, et al.

*Ann Rheum Dis* published online May 14, 2012
doi: 10.1136/annrheumdis-2011-201165

Updated information and services can be found at:
http://ard.bmj.com/content/early/2012/05/14/annrheumdis-2011-201165.full.html

These include:

- **Data Supplement**
  "Web Only Data"
  http://ard.bmj.com/content/suppl/2012/05/14/annrheumdis-2011-201165.DC1.html

- **References**
  This article cites 56 articles, 20 of which can be accessed free at:
  http://ard.bmj.com/content/early/2012/05/14/annrheumdis-2011-201165.full.html#ref-list-1

- **Email alerting service**
  Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Advance online articles have been peer reviewed, accepted for publication, edited and typeset, but have not not yet appeared in the paper journal. Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication.

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/
Articles on similar topics can be found in the following collections

- Immunology (including allergy) (3353 articles)
- Degenerative joint disease (3107 articles)
- Musculoskeletal syndromes (3343 articles)
- Epidemiology (949 articles)
- Connective tissue disease (2852 articles)
- Rheumatoid arthritis (2147 articles)
- Systemic lupus erythematosus (408 articles)

Advance online articles have been peer reviewed, accepted for publication, edited and typeset, but have not yet appeared in the paper journal. Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication.

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/